PT-141 (Bremelanotide): Complete Guide

What Is PT-141?

PT-141, also called bremelanotide, is a synthetic cyclic heptapeptide that acts on melanocortin receptors, particularly MC4R. The prescription drug Vyleesi contains bremelanotide and has an FDA-approved indication for a specific form of HSDD in premenopausal women.

How Does PT-141 Work?

Bremelanotide activates several melanocortin receptor subtypes. According to the current prescribing information, MC1R and MC4R are particularly relevant at therapeutic concentrations. However, the FDA label notes that the precise mechanism by which bremelanotide improves HSDD remains unknown.

PT-141 and Sexual Desire

Research surrounding bremelanotide has focused on sexual desire and arousal, particularly in women with HSDD. Importantly, its FDA-approved use is narrower than many online descriptions suggest: it is not approved as a general sexual-performance enhancer and is not indicated for HSDD in men or postmenopausal women.

PT-141 Safety and Side Effects

The prescribing information identifies nausea, transient increases in blood pressure, reductions in heart rate, and focal hyperpigmentation among important safety considerations. Appropriate medical evaluation is therefore important before using prescription bremelanotide.

PT-141 Research vs. Approved Medication

A useful distinction for SEO content is between PT-141 as a research/compound name and bremelanotide as the active ingredient in an FDA-approved prescription medicine. Products sold through research-chemical channels should not automatically be treated as equivalent to an approved pharmaceutical product.